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Abstract Androgen-induced growth factor (AIGF) has 
hormone-regulated properties in the mouse Shionogi carcinoma 
cell line. To investigate whether or not it is involved in growth of 
human hormone-responsive cancers, we isolated the human AIGF 
gene from a placental genomic library. Genomic analyses sug- 
gested that the AIGF gene was about 6.5 kilobases in length 
containing five exons. The deduced amino acid sequence of human 
AIGF was completely identical with that of the mouse. RT-PCR 
analyses showed that prostate and breast cancer cell lines, 
LNCaP, PC-3, and MCF-7, slightly expressed the AIGF gene. 
Recombinant AIGF enhanced the growth of the human prostate 
cancer LNCaP cells, and it also markedly stimulated the growth 
of fibroblasts. These in vitro findings suggest hat AIGF might 
be a possible autocrine or paracrine factor in hormone-responsive 
cancers. 
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I. Introduction 
involved in mesenchymo-epithelial p racrine interaction in the 
normal prostate and prostate cancers [1,18]. These findings 
have led us to investigate whether or not A IGF  is involved in 
the hormone-responsive growth of prostate and breast cancers. 
In this study, we first present molecular cloning of the human 
A IGF  gene. And then, we show possible autocrine or paracrine 
functions of A IGF  in human prostate and breast cancer cells. 
2. Materials and methods 
2.1. Cell lines 
LNCaP, PC-3, ZR75-1 and MCF-7 cells were purchased from 
Dainippon Pharmacy Corp. (Osaka, Japan). NIH 3T3 cells were gifted 
from National Cardiovascular Center Research Institute. LNCaP cells 
were maintained in RPMI 1640 medium supplemented with 10% fetal 
bovine serum (FBS). PC-3 cells were maintained in Ham's F12-K me- 
dium containing 10% FBS. MCF-7 cells were maintained inDulbecco's 
modified Eagle medium (DMEM) medium supplemented with 10% 
FBS and 10 nM 17fl-estradiol. ZR75-1 cells were maintained in RPMI 
1640 medium supplemented with 10% FBS. NIH 3T3 cells were main- 
tained in DMEM medium containing 10% FBS. SC-3 cells were cloned 
and maintained as reported [11]. During studies of hormone stimula- 
tion, intrinsic steroids were stripped from FBS using dextran-coated 
charcoal. 
The fibroblast growth factor (FGF) family is involved in 
various biological processes uch as animal development, neu- 
rogenesis, and angiogenesis (reviewed in [1]). Nine members 
have been identified to date. Acidic and basic FGFs  are proto- 
typal and they play various important roles [2]. Int-2/FGF-3, 
Hst- I /FGF-4, FGF-5, and FGF-6 were originally isolated as 
oncogene products [3,4,5,6], and are mainly expressed at vari- 
ous developmental stages in the normal embryo [7,8,9,10]. An- 
drogen-induced growth factor (AIGF)/FGF-8 has been iso- 
lated from the conditioned medium of the androgen-dependent 
mouse mammary Shionogi carcinoma cell line (SC-3) stimu- 
lated with testosterone [11]. A IGF  is secreted by SC-3 cells in 
response to androgenic stimuli, and then it stimulates the 
growth of the cells in an autocrine manner [11]. Since A IGF  has 
hormone-inducible and oncogenic features in SC-3 cells, A IGF  
is suspected to play important roles on the growth of human 
hormone-responsive breast and prostate cancers. In addition, 
FGFs or FGF  receptors (FGFRs) are often overexpressed in 
various types of carcinomas and seem to contribute to the 
progression of these tumors [12,13,14]. Especially basic FGF  
is well-known to be an important factor for benign and malig- 
nant growth of prostate cells [15,16,17], and keratinocyte 
growth factor (KGF)/FGF-7 is recently suggested to be 
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2.2. RNAs 
Total cellular RNAs were extracted from subconfluent testosterone- 
stimulated or non-stimulated LNCaP and PC-3 cells using acid gua- 
nidium isothiocyanat~phenol-chloroform [19]. Total cellular RNAs 
were also extracted from subconfluent MCF-7, ZR75-1 and testoster- 
one-stimulated SC-3 cells. 
2.3. Southern blotting 
DNAs were electrophoresed in agarose gels and transferred onto 
nylon membranes. Hybridization was performed in 5xSSPE 
(1 x SSPE = 0.15 M NaCI/10 mM phosphate, pH 7.4ll mM EDTA) 
containing 5x Denhardt's olution (1 x Denhardt's olution = 0.02% 
bovine serum albumin/0.02% Ficoll/0.02% polyvinylpyrrolidone) and 
0.5% SDS at 65°C for 18 h. Blots were subsequently washed with 
2 x SSC (l x SSC --- 0.15 M NaCI/0.015 M sodium citrate) containing 
0.1% SDS at 50°C for 30 min and 0.1 x SSC containing 0.5% SDS at 
50°C for 30 rain. 
2.4. Isolation of human A1GF genomic clones 
A human placental genomic phage library, purchased from Strat- 
agene (La Jolla, CA), was screened. In total, 5x 105 clones were 
screened using a 32p-labeled whole mouse AIGF cDNA probe. Isolated 
DNAs were subcloned into the Blue Script II vector (Stratagene) for 
further analysis. 
2.5. Nucleotide s quencing 
Restriction enzyme mapping and Southern blotting showed that 
most of the positive clones contained similar fragments hybridized with 
the mouse AIGF probe. The four hybridized fragments shown in Fig. 
1A (1.0 kb NotI-PstI, 0.7 kb Pstl-PstI, 0.8 kb BamHI-KpnI, and 1.5 kb 
XhoI-SacI fragments) were subcloned into the Blue Script II vector and 
sequenced by dideoxynucleotide chain-termination [20] using a cycle 
0014-5793/95/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI 00 14-5793(95)00324-X 
A. Tanaka et al. IFEBS Letters 363 (1995) 226-230 227 
sequencing kit and a DNA sequencer (Applied Biosystems Division, 
Perkin Elmer Cetus, Norwalk, CT). The sequence was determined on 
both strands. 
2.6. RT-PCR 
Two primer sequences were used to amplify human and mouse 
AIGF: the 5'-primer was 5'-TTTACACAGCATGTGAGGGAG-3' 
(nucleotide sequences from 264 to 284 in Fig. 1B) and the 3'-primer was 
5'-GTAGTTGAGGAACTCGAAGCG-Y (nucleotide sequences from 
758 to 738). Both sequences are common to human and mouse AIGFs. 
Glyceraldehyde 3-phosphate dehydrogenase (G-3-PDH) control prim- 
ers which are common to human and mouse were purchased from 
Clontech (Palo Alto, CA). The eDNA was synthesized from 500 ng of 
total RNA using the 3'-primer and the RT-PCR kit (GeneAmp RNA 
PCR Kit; Perkin Elmer Cetus). Samples were cycled for PCR 35 times 
at 95°C for 1 min, at 55°C for 1 min, and 72°C for 1 rain with total 
volume of 100 ¢tl. Ten ¢tl of PCR-amplified samples were electrophor- 
esed in 2% agarose gels, and stained with ethidium bromide. These 
fragments were further analyzed by Southern blotting using the whole 
mouse AIGF eDNA probe. The Intensity of the hybridized AIGF band 
of each lane was measured by a laser densitometer (Pharmacia LKB, 
Uppsala, Sweden). Some of the PCR-amplified fragments were purified 
and ligated into the pGEM-T vector (Promega, Madison, WI). The 
nucleotides of the amplified fragments were sequenced as described 
above. 
2. 7. Preparation of recombinant AIGF 
Since amino acid sequences of human and mouse AIGF are com- 
pletely identical, recombinant AIGF was prepared from an isolated 
stable cell line transfected with the mouse AIGF eDNA. Namely, the 
mouse AIGF eDNA was subcloned into the eukaryotic expression 
vector, pSD(X)-dhfr, containing the mouse dihydrofolate reductase 
gene as a selective marker. The resulting expression plasmid, pSD(X)- 
dhfr-AIGF, was transfected into CHO(dhfr-) cells by the calcium 
phosphate precipitation method. Recombinant AIGF was purified 
from the supernatant of the isolated clonal CHO cell line as reported 
[11], 
2.8. Cell proliferation assay 
LNCaP and PC-3 cells (4 x 104 cells/dish) were plated onto 35 mm- 
dishes containing 1.5 ml of Ham's F12: Eagle's minimum essential 
medium (MEM) (1:1; v/v) supplemented 2% FBS treated with dextran- 
coated charcoal. On the following day (day 0), the medium was changed 
to 1.5 ml of the medium with or without 10 ng/ml basic FGF (Pepro 
Tech Inc., Rocky Hill, NJ), 10 ng/ml recombinant AIGF, or 10 nM 
testosterone. The medium was changed every other day. Three or four 
dishes were used for each samples. Cells were counted on day 5. On the 
other hand, NIH 3T3 cells (5 × 103 cells/well) were plated onto a 24-well 
plate containing 1 ml of RPMI 1640 supplemented with 2% FBS. After 
5 h plating, the medium was changed to the medium with or without 
test compounds. The medium was changed every other day. Three wells 
were used for each samples. Cells were counted on day 6. 
3. Resu l t s  
3.1. Isolation and characterization of the human AIGF gene 
Genomic analyses howed that the human A IGF  gene was 
6.5 kb in length and that it contained five exons (Fig. 1A). 
Highly conserved sequences between mouse and human A IGF  
allowed us to tentatively determine the human A IGF  eDNA 
sequence (Fig. 1B). Later, sequencing of the amplified RT-PCR 
fragments verified the nucleotide sequence from 264 to 758. The 
deduced amino acid sequence of human A IGF  was completely 
identical with that of the mouse. 
3.2. RT-PCR analysis for human AIGF expression in prostate 
and breast cancer cell lines 
The expression of A IGF  in human prostate or breast cancer 
cell lines was examined by means of RT-PCR. In the androgen- 
responsive and unresponsive prostate cancer cell lines, LNCaP 
and PC-3, respectively, low levels of amplified A IGF  fragments 
were detected in the presence or absence of testosterone (Fig. 
2A). Measured by a laser densitometer, the levels of A IGF  
expression of both cell lines under testosterone-stimulated or 
non-st imulated conditions were almost similar. Compared with 
that of SC-3 cells, the densitometric levels of these lanes were 
about 40%. However, no growth-promoting activity was found 
in their condit ioned media when assayed by SC-3 cells (data not 
shown). The amplified A IGF  fragment was also detected in the 
estrogen-responsive breast cancer cell line, MCF-7,  but not 
ZR75-1,  which is also an estrogen-responsive br ast cancer cell 
line (Fig. 2B). 
t t l kb  
E 
Exon I II III IV  V 
r-"l 0.2kb 
B: BamHI 
K: Kpn I 
N: Not I 
X: Xho I 
P: Pst I 
S: Sac I A 
Fig. 1. (A) Restriction enzyme map of the human AIGF locus. Subclones used for nucleotide sequencing are shown below. Five identified exons 
are boxed. Abbreviations for the restriction enzymes ites are: B, BamHI; K, KpnI; N, NotI; X, XhoI; P, PstI; S, Sael. 
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Mouse CGC . . . . . . . . . . . . . . . .  A . . . . . .  C . . . . . . . .  C . . . . . . . . . . .  G - - -A -  
Human 1 GCGGCGCGGCGAGCACGACGTTCCACGGGACCCGCGGAGCCGCGTCGTGATCG 
Mouse . . . .  T . . . . . . . . . . . . . .  CG- - -TC-CT-AGC-T -CG-ACCT- -G- -TT  . . . .  C . . . . .  
Human 54 CCGCCGGCCTCCCGCACCCGCACCCTCTCCGCTCGCGCCCTGCTCAGCGCGTCCTCCCGC 
Mouse - - -CT- -A -T  . . . . . . . . . . . . . . .  C- -T  . . . . . . . . .  A . . . .  T . . . . . . . . . . . . . . . .  
Human 114 GGCGGCCCGCGGGACGGCGTGACCC GC CGGGCTCTCGGTGC CCCGGGGCCGCGCGCC 
Mouse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Human 171ATGGGCAGCCCCCGCTCCGCGC/GAGCTGCCT~t  . . . . .  cagGCTGTTGCACTTGCTG 
M G S P R S A L S C L L L H L L 
Mouse - -T  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Human 219  GTCCTCTGCCTCCAAGCCCAG~aq.q . . . . .  aa~TAACTGTTCAGTCCTCACCTAATTTT 
V L C L g A Q V T V O S S P N F 
Mouse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Human 267  ACACAGCATGTGAGGGAGCAGAGCCTGGTGACGGATCAGCTCAGCCGCCGCCTCATCCGG 
T Q H V R E G S L V T D Q L S R R L I R 
Mouse . . . . . . . .  G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Human 327 ACCTACCAACTCTACAGCCGCACCAGCGGGAAGCACGTGCAGGTCCTGGCCAACAAGCGC 
T Y O L Y S R T S G K H V Q V L A N K R 
Mouse . . . . . . . . . . . . . . . . .  A . . . . .  A . . . . . . . . . . .  6 . . . . . . . .  T - - -  
Human 387 ATCAACGCCATGGCAGAGGACGGCGACCCCTTCGotaaq.q  . . . . .  caqCAAAGCTCATCGTG 
I N A M A E D G D P F A  K L I V  
Mouse . . . . .  C - -T - - /  . . . . . . . . . . . . . .  C . . . . .  T - -C - -C - -A  . . . . .  A - -T  . . . . . . . . .  
Human 435 GAGACGGACACCTTTGGAAGCAGAGTTCGAGTCCGAGGAGCCGAGACGGGCCTCTACATC 
E T D T F G S R V R V R G A E T G L Y I 
Mouse . . . . . . . . . . . . . . . . . . . . . . .  A- -T  . . . . . . . . . . . . . . . . . . . . .  
Human 495 TGCATGAACAAGAAGGGGAAGCTGATCGCCAAG~a~ . . . . .  ca~GCAACGGCAAAGGC 
C M N K K G K L I A K S N G K G 
Mouse . . . . . . . . . . . .  A . . . . .  A . . . . .  C . . . . . . . . . . . . . . . . . . . .  G . . . . . . . . . . .  C - - -  
Human 543 AAGGACTGCGTCTTCACGGAGATTGTGCTGGAGAACAACTACACAGCGCTGCAGAATGCC 
K D C V F T E ] V L E N N Y T A L Q N A 
Mouse . . . . . . . . . . . . . . . . . . . . . . . . . .  T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Human 603 AAGTACGAGGGCTGGTACATGGCCTTCACCCGCAAGGGCCGGCCCCGCAAGGGCTCCAAG 
K Y E G W Y M A F T R K G R P R K G S K 
Mouse . . . . .  C . . . . .  T . . . . .  C . . . . .  G . . . . . . . . . . . . . .  C . . . . .  G . . . . . . . . . . . . . . .  
Human 663 ACGCGGCAGCACCAGCGTGAGGTCCACTTCATGAAGCGGCTGCCCCGGGGCCACCACACC 
T R Q H Q R E V H F M K R L P R G H H T 
Mouse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Human 723 ACCGAGCAGAGCCTGCGCTTCGAGTTCCTCAACTACCCGCCCTTCACGCGCAGCCTGCGC 
T E Q S L R F E F L N Y P P F T R S L R 
Mouse . . . . . . . . . . . . . . . . . . . . . . .  G . . . . . . . . . . . . .  C - - -C - - -CA- -T  . . . . . . . . .  C 
Human 783 GGCAGCCAGAGGACTTGGGCCCCCGAGCCCCGATAGGTGCT GCCTGGC CCTCCCCACA 
G S Q R T W A P E P R * 
Mouse CA- - -G  . . . .  AG- -A  - -C - - -  GG . . . . .  C 
Human 841 ATGCCAGACCGCAGAGAGGCTCATCCTGTAGGGCACCCAAAACTCAAGCAAGATGAGCTG 
Mouse G . . . . .  A -A - - -AA  . . . . . . .  G . . . . . . . . . . . .  CC- - -TA  . . . . .  GC . . . . .  
Human 901 TGCGCTGCTCTGCAGGCTGGGGAGGTGCTGGGGGAGCCCTGGGTTCCGGTTGTTGATATT 
Mouse . . . . . . . . . . . . . . . . . .  TTGT . . . . .  G . . . . . .  G . . . . .  G . . . .  TTGTTTTTT . . . . . .  
Human 961 GT/TGCTGTTGGGTTTTTGCTGTTTTTTTTTTTTTTTTTTTTTTT AAAACAA 
Mouse . . . . .  AGG-G 
Human 1013 AAGAGGC/CT B 
Fig. 1. (B) Nucleotide and amino acid sequences of human AIGF compared with the mouse. Human ucleotide s quences are numbered according 
to the numbers of mouse AIGF cDNA [11]. The exon intron boundaries are shown in italics. Identical nucleotide sequences are shown in dashes. 
Gaps were introduced to maximize homology. 
3.3. Effects of recombinant AIGF on growth of cultured cell lines 
Preliminary experiments using the purified recombinant 
AIGF showed that it markedly stimulated the growth of 
SC-3 cells in a dose-dependent manner and its EDso value was 
about 10 ng/ml (data not shown). When stimulated by 10 
ng/ml recombinant AIGF, 10 ng/ml basic FGF, or l0 nM 
testosterone, the growth of LNCaP cells were enhanced up 
to the levels of 150%, 230% or 300%, respectively, compared 
with the control (100%) in cell number. PC-3 cells were not 
stimulated by these compounds. The growth of NIH 3T3 
cells was markedly stimulated in the presence of 10 ng/ml 
recombinant AIGF or 10 ng/ml basic FGF up to the level 
of 340% or 200%, respectively, compared with the control 
(Fig. 3). 
4. Discussion 
The nucleotide sequences of AIGF were highly conserved 
between mouse and human. There were only 30 silent nucleo- 
tide changes in the coding region compared with mouse AIGF. 
The deduced amino acid sequence of human AIGF was com- 
pletely identical with that of the mouse. The high degree of 
amino acid homology implied that AIGF had a highly con- 
served function. Recently, Ohuchi et al. have suggested from 
their in situ hybridization studies that AIGF plays important 
biological roles on brain development or limb and facial mor- 
phogenesis [21]. More studies uch as homologous recombina- 
tion experiments will elucidate distinct biological roles of 
AIGF. 
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A B 
1 2 3 4 5 M 1 6 7 M 
-560 bp 
AIGF 
G3PDH 
Fig. 2. RT-PCR analysis of AIGF expression i  various human prostate and breast cancer cell lines. (A) RT-PCR analysis of AIGF expression i  
the human prostate cancer cell lines, PC-3 and LNCaE Total RNAs obtained from the PC-3 or LNCaP cells stimulated or not with testosterone 
were reverse-transcribed an  the cDNAs were amplified 35 cycles of PCR by using AIGF or G-3-PDH primers as described in section 2. RT-PCR 
products were electrophoresed in agarose gels, stained with ethidium bromide and analyzed by Southern blotting using the whole mouse AIGF cDNA 
probe. The arrow indicates the position of AIGF. SC-3 cells were used for the positive control. Lane 1 = SC-3 cells; lane 2 -- testosterone-stimulated 
PC-3 cells; lane 3 = non-stimulated PC-3 cells; lane 4 = testosterone-stimulated LNCaP cells; lane 5 = non-stimulated LNCaP cells; M = molecular 
weight marker. (B) RT-PCR analysis of AIGF expression i human breast cancer cell lines, MCF-7 and ZR75-1. AIGF expression was also examined 
by RT-PCR in both breast cancer cells. Lane 1 = SC-3 cells; lane 6 = ZR75-1 cells; lane 7 = MCF-7 cells; M = molecular weight marker. 
In general, genes of the FGF  family contain three exons with 
similar exon-intron boundaries [3,4,6,22]. Exons IV and V of 
the A IGF  gene are well correlated with the second and third 
exons of other FGF  genes. On the other hand, the equivalent 
of the first exon of other FGF  genes is divided into three small 
exons (exons I, II, and III in Fig. 1A) in the A IGF  gene. 
Previously, using the SC-3 mouse mammary  cancer cell line, we 
reported an isoform of mouse A IGF  which was alternatively 
spliced at the 5'-upstream port ion of the exon III [11]. In this 
study, the isoform was not precisely determined even after full 
sequencing of the second intron (data not shown). 
We previously demonstrated that A IGF  mediates the andro- 
gen-dependent growth of the mouse mammary  Shionogi carci- 
noma SC-3 cells [11]. The findings obtained from these cells 
strongly suggested that hormone- induced growth factors are 
also involved in human prostate and breast cancers. Many 
investigators have reported that various growth factors are 
involved in growth of these cancers (reviewed in [23,24]). How- 
ever, no distinct hormone- induced growth factors have yet been 
identified in human prostate and breast cancers as far as we 
know. Al though KGF/FGF-7  is suggested to be a paracrine 
growth factor which is secreted from stromal cells in response 
to androgenic stimuli in a rat prostate cancer model [18], its 
involvement of the human cancers have not been elucidated yet. 
In this study, we presented that A IGF  was slightly expressed 
in the prostate cancer cell lines, LNCaP and PC-3, under both 
testosterone-stimulated and non-st imulated conditions. The 
cell growth experiments showed that LNCaP cells actually in- 
creased in cell number, responded to exogenous AIGF.  These 
results howed possibilities that A IGF  could make an autocrine 
loop in prostate cancers. However, unlike the mouse mammary  
-~ 3oo- 
O 
"6 
"-~ 200-  
tY  
i -  
,o 
100- 
u i 
CFAT 
PC-3 
F 
CFAT CFA 
LNCaP NIH3T3 
Fig. 3. Effects of recombinant AIGF (A; 10 ng/ml), basic FGF (F; 10 
ng/ml), or testosterone (T; 10 nM) on growth of LNCaP, PC-3, and 
NIH 3T3 cells. LNCaP, and PC-3, and NIH 3T3 cells were plated, 
cultured, and examined for growth as described in section 2. Results 
were expressed as percent of each control (C). Actual mean numbers 
of the controls were: LNCaP, 5.0 x 104; PC-3, 24.8 x 104: NIH 3T3, 
14.6 x 105. Values = means of 34  determinations; bars = S.E.M.; 
*P < 0.01, **P < 0.001, when compared to each control. The other trial 
gave similar result. 
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Shionogi carcinoma cells, hormone-regulated properties of 
AIGF were not clear in the human prostate cancer ceils. More 
studies will be expected to elucidate the actual properties of 
AIGF. The cell growth experiments also showed that AIGF 
was a strong mitogen for fibroblasts. Ohuchi et al. suggested 
in their developmental study that AIGF should be an epithelial 
factor that mediates epithelio-mesenchymal interactions [21]. 
Although specific functions of AIGF have not yet been eluci- 
dated, it is possible that AIGF may act as a paracrine growth 
factor on cancer growth. 
In summary, we presented here, using several human cancer 
cell lines, that AIGF might be a possible autocrine or paracrine 
factor in hormone-responsive cancers. However, hormone-reg- 
ulated properties of AIGF was not demonstrated in this study. 
More extensive studies using human surgical materials will 
provide more informations about actual properties of AIGF in 
human hormone-responsive cancers. 
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